EMC Capital Management Purchases Shares of 3,420 LivaNova PLC $LIVN

EMC Capital Management acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,420 shares of the company’s stock, valued at approximately $154,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Primecap Management Co. CA lifted its position in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after purchasing an additional 32,942 shares during the period. Vanguard Group Inc. increased its holdings in LivaNova by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock valued at $104,755,000 after buying an additional 316,993 shares during the period. AQR Capital Management LLC raised its stake in shares of LivaNova by 111.7% in the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after buying an additional 829,115 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of LivaNova by 1.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,429,740 shares of the company’s stock worth $64,374,000 after acquiring an additional 18,551 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of LivaNova by 100.7% during the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company’s stock worth $39,398,000 after acquiring an additional 503,350 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the stock a “neutral” rating in a research report on Wednesday, October 1st. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Robert W. Baird increased their target price on LivaNova from $63.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Mizuho raised their target price on LivaNova from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.43.

LivaNova Stock Performance

NASDAQ:LIVN opened at $53.89 on Wednesday. The stock has a market capitalization of $2.94 billion, a P/E ratio of -13.85 and a beta of 1.00. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $58.91. The firm has a 50 day moving average of $53.52 and a 200-day moving average of $49.25.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business had revenue of $357.80 million for the quarter, compared to analyst estimates of $342.32 million. During the same period in the prior year, the company earned $0.90 EPS. LivaNova’s revenue for the quarter was up 12.5% on a year-over-year basis. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, sell-side analysts anticipate that LivaNova PLC will post 2.85 EPS for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.